Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Text search

Sort by Date

Click to order products descending

Display 30 Products per page

Disease Analysis: Chronic Heart Failure
Read More
Chronic heart failure (CHF) is a progressive condition in which the heart muscle is unable to pump enough blood to meet the needs of the body. CHF can result from functional abnormalities such as ventricular dysfunction or arrhythmias, or structural disorders of the myocardium or valves.
June 30, 2022
Find out more
Disease Analysis: Prostate Cancer
Read More
Prostate cancer occurs when malignant cells originate in the prostate gland. The vast majority of prostate cancers are adenocarcinomas, but other less common types include sarcomas, small cell carcinomas, neuroendocrine tumors, and transitional cell carcinomas. Some prostate cancers can grow and spread quickly, but many are relatively indolent. Because of this, depending on patient age and other co-morbidities, some prostate cancer patients may not receive active treatment for the disease during their lifetime.
June 24, 2022
Find out more
Disease Analysis: Melanoma
Read More
Melanoma accounts for just 1% of all skin cancer cases, but is responsible for the majority of skin cancer-related deaths. Melanoma occurs when melanocytes – pigment-producing cells of the skin that are intercalated in the basal cell layer – become malignant. Although surgical excision is a potentially curative option for many melanoma patients, the disease can disseminate rapidly. Currently, only 27.3% of patients diagnosed with distant metastatic melanoma survive for five years, compared to about 99.0% of those with localized disease. Although 83% of patients present with localized disease, approximately one quarter to one third of these patients will eventually experience disease recurrence.
June 22, 2022
Find out more
Disease Analysis: Chronic Myeloid Leukemia (CML)
Read More
Chronic myeloid leukemia (CML) is defined as a cancer of the blood in which a mutation in myeloid hematopoietic stem cells causes the overproduction of immature and dysfunctional white blood cells (myeloblasts, also known as blasts), preventing the normal production and function of healthy white blood cells, red blood cells, and platelets.
June 20, 2022
Find out more
Disease Analysis: Migraine
Read More
Migraine is a common, disabling, and recurring neurological disorder characterized by severe headache co-occurring with nausea, vomiting, and other symptoms, the duration of which can range from hours to days.
June 16, 2022
Find out more
Disease Analysis: Chronic Obstructive Pulmonary Disease (COPD)
Read More
The “ABCD” GOLD treatment guidelines focus on exacerbation risk and patient-reported outcomes to determine pharmacological treatment strategies, independent of spirometric value. Dual bronchodilator combinations are being considered as the new gold standard over long-acting muscarinic antagonist Spiriva in the treatment of more severe COPD.
June 15, 2022
Find out more
Interventional Neurology: Mechanical Thrombectomy Devices

$4,750.00

Mechanical thrombectomy (MT) is an emergency surgical technique used in eligible patients experiencing acute ischemic stroke (AIS) to remove a blood clot in the brain. In 2021, the combined global market for neuroendovascular MT devices was estimated at approximately $706m.
June 14, 2022
Find out more
Disease Analysis: Colorectal Cancer
Read More
Colorectal (or bowel) cancer refers to carcinomas arising in the epithelium of the large intestine at any point between the cecal valve and the anus. CRC typically develops through the proliferation of mucosal epithelial cells of the gastrointestinal (GI) wall, eventually forming a polyp or adenoma. As with many other cancers of the GI tract, the vast majority (>95%) are adenocarcinomas.
June 13, 2022
Find out more
Disease Analysis: Anemia in Chronic Kidney Disease
Read More
Anemia in chronic kidney disease (CKD), defined as a reduction in red blood cells (RBCs) or hemoglobin levels, often results from decreased levels of erythropoietin and increased levels of hepcidin. Erythropoietin is primarily produced in the kidneys and increases the production of RBCs by acting on precursor cells. H
June 7, 2022
Find out more
Market Spotlight: Obesity

$1,318.00

This Market Spotlight report covers the Obesity market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecast
June 3, 2022
Find out more
Market Spotlight: Hepatitis B

$1,318.00

This Market Spotlight report covers the Hepatitis B market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
May 26, 2022
Find out more
Drug Delivery: Transdermal Devices

$4,750.00

This chapter provides a discussion of the sales, competitors, drivers, and limiters of the transdermal drug delivery devices market in the areas of cardiovascular disease (CVD; eg angina pectoris and hypertension), neurological disorders (eg attention deficit hyperactivity disorder [ADHD], major depressive disorder [MDD], Alzheimer’s disease, and Parkinson’s disease), hormone replacement therapy (HRT; eg menopause and osteoporosis treatment), and pain management (eg fentanyl- and lidocaine-based chronic pain treatment). Markets covered by this analysis include the US, Japan, the five major European markets (France, Germany, Italy, Spain, and the UK), and the rest of world (RoW) markets.
May 26, 2022
Find out more
Neuromodulation: Deep Brain Stimulation and Vagus Nerve Stimulation Devices Market

$4,750.00

This report provides an overview of primary neurological diseases/disorders treated with deep brain stimulation (DBS) and vagus nerve stimulation (VNS), as well as overviews of DBS and VNS neuromodulation technologies, competitors, sales, forecasts, and competitive and market analysis. Markets covered by this analysis comprise the US, Japan, the five major European markets (France, Germany, Italy, Spain, and the UK), and the Rest of World (RoW) markets.
May 26, 2022
Find out more
Market Spotlight: Overactive Bladder

$1,318.00

This Market Spotlight report covers the Overactive Bladder market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
May 25, 2022
Find out more
Disease Analysis: Multiple Myeloma
Read More
Multiple myeloma (MM) is a hematological malignancy characterized by the infiltration of malignant, antibody-producing plasma cells in the bone marrow. The disease represents approximately 1% of all cancers, and 10% of hematological cancers. The hallmarks of MM are high levels of monoclonal (M-) protein, high levels of clonal plasma cells in the bone marrow, and organ damage.
May 25, 2022
Find out more
Market Spotlight: Primary Sclerosing Cholangitis (PSC)

$1,318.00

This Market Spotlight report covers the Primary Sclerosing Cholangitis (PSC) market, comprising key pipeline drugs, recent events and analyst opinion, upcoming events, clinical trials, probability of success, licensing and asset acquisition deals, and a 10-year disease prevalence forecast.
May 25, 2022
Find out more
Market Spotlight: Cutaneous T-Cell Lymphoma (CTCL)

$1,318.00

This Market Spotlight report covers the Cutaneous T-Cell Lymphoma (CTCL) market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, recent events and analyst opinion, probability of success, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
May 25, 2022
Find out more
Market Spotlight: Systemic Lupus Erythematosus (SLE)

$1,318.00

This Market Spotlight report covers the Systemic Lupus Erythematosus (SLE) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
May 23, 2022
Find out more
Market Spotlight: Hodgkin’s Lymphoma

$1,318.00

This Market Spotlight report covers the Hodgkin’s Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, recent events and analyst opinion, a 10-year disease incidence and prevalence forecast, probability of success, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.
May 23, 2022
Find out more
Colorectal Cancer KOL Interview – UK

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into current prescribing habits, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for colorectal cancer. Key assets highlighted include Avastin/bevacizumab, Erbitux, Vectibix, Mektovi, Braftovi, Cyramza, Lonsurf, Jemperli, Opdivo, Yervoy, Tecentriq, Cosela, Modufolin, fruquintinib, adagrasib, and sotorasib.
May 23, 2022
Find out more
Colorectal Cancer KOL Interview – US, Northeast

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into current prescribing habits, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for colorectal cancer. Key assets highlighted include Avastin/bevacizumab, Erbitux, Vectibix, Mektovi, Braftovi, Cyramza, Lonsurf, Jemperli, Opdivo, Yervoy, Tecentriq, Cosela, Modufolin, fruquintinib, adagrasib, and sotorasib.
May 23, 2022
Find out more
Disease Analysis: Pulmonary Hypertension
Read More
Pulmonary hypertension (PH) is a life-threatening and often fatal disease characterized by abnormal vascular proliferation and remodeling of the small pulmonary arteries and arterioles, vasoconstriction, and in situ thrombosis. This leads to a progressive increase in pulmonary vascular resistance (PVR) and, ultimately, the development of right ventricular (RV) dysfunction. Cornerstone histopathological features of the PH vasculopathy include intimal thickening, concentric hypertrophy, and perivascular fibrosis of distal pulmonary arterioles.
May 20, 2022
Find out more
Disease Analysis: Triple-Negative Breast Cancer
Read More
Triple-negative breast cancer (TNBC) is a relatively rare breast cancer subtype. It is characterized by the absence of estrogen and progesterone receptors and does not involve the overexpression of HER2. TNBC is associated with poor prognosis, a high risk of local recurrence, and poor disease-free and cancer-specific survival. It accounts for roughly 14% of breast cancers.
May 20, 2022
Find out more
Disease Analysis: HR+/HER2- Breast Cancer
Read More
Hormone receptor-positive (HR+) is the most common breast cancer subtype, with approximately 70% of breast cancers presenting with overexpression of estrogen receptors, progesterone receptors, or both (De Placido and Pronzato, 2015). Overexpression of the hormone receptors allows estrogen and progesterone to drive tumor growth and proliferation. Therefore, endocrine therapy remains the standard treatment for advanced patients with HR+/human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
May 20, 2022
Find out more
Disease Analysis: HER2+ Breast Cancer
Read More
Amplification of the HER2/neu oncogene and related genetic elements on chromosome 17 increases HER2 expression and accelerates tumorigenesis. The natural disease progression meant that, historically, women with breast cancer who overexpressed HER2 were found to have significantly shorter disease-free survival and overall survival compared with women without HER2 amplification; however, the introduction of trastuzumab in 1998 drastically changed patient outcomes, to the point where HER2+ breast cancer patients now have the longest median survival of all breast cancer subtypes. HER2 is overexpressed in approximately 20% of breast cancers.
May 20, 2022
Find out more
Market Spotlight: Pancreatic Cancer

$1,318.00

This Market Spotlight report covers the Pancreatic Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
May 19, 2022
Find out more
Market Spotlight: Neuropathic Pain

$1,318.00

This Market Spotlight report covers the neuropathic pain market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
May 19, 2022
Find out more
Market Spotlight: Small-Cell Lung Cancer (SCLC)

$1,318.00

This Market Spotlight report covers the Small Cell Lung Cancer (SCLC) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, probability of success, clinical trials, upcoming and regulatory events, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
May 19, 2022
Find out more
Disease Analysis: Hepatocellular Carcinoma (HCC)
Read More
Liver cancers can be differentiated based on the cell types they affect. The most common form of liver cancer is hepatocellular carcinoma (HCC), which accounts for 80–90% of liver cancer cases. HCC affects hepatocellular cells, or hepatocytes, which are the most abundant cell type in the liver and are responsible for the liver’s primary functions, such as bile production, protein synthesis, and detoxification. This differentiates HCC from other types of liver cancer such as cholangiocarcinoma, which affects the epithelial cells lining the bile ducts, and angiosarcoma, which affects the endothelial cells lining blood vessels of the liver.
May 19, 2022
Find out more
Disease Analysis: Ovarian Cancer
Read More
Ovarian cancer is defined as a group of tumors that originate in the ovaries. Most ovarian cancers are epithelial carcinomas which begin in the tissue surrounding the ovary. Other less common types of ovarian tumors include primary peritoneal, fallopian tube, and malignant germ cell tumors. Ovarian cancer is the fourth most common cancer among women, and is the leading cause of gynecological cancer-related death in women.
May 19, 2022
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *